Edwards Lifesciences Corporation $EW Shares Sold by Cinctive Capital Management LP

Key Points

• Cinctive Capital Management LP reduced its holdings in Edwards Lifesciences Corporation by 34.9%, owning 96,950 shares after selling 51,973 shares during the first quarter.
• Various institutional investors have increased their stakes in Edwards Lifesciences, with Jennison Associates LLC raising their position by 34.3% and owning over 10 million shares worth approximately $731 million.
• Despite the decrease in shareholding from Cinctive, analysts maintain a generally positive outlook on Edwards Lifesciences, with an average rating of "Moderate Buy" and a target price of $85.90.

Cinctive Capital Management LP decreased its holdings in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 34.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 96,950 shares of the medical research company's stock after selling 51,973 shares during the period. Cinctive Capital Management LP's holdings in Edwards Lifesciences were worth $7,027,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in EW. Vega Investment Solutions bought a new position in shares of Edwards Lifesciences during the 4th quarter valued at approximately $27,000. Quantbot Technologies LP purchased a new position in shares of Edwards Lifesciences during the 1st quarter worth about $26,000. SouthState Corp bought a new position in Edwards Lifesciences during the 1st quarter valued at about $27,000. Rossby Financial LCC bought a new stake in Edwards Lifesciences in the first quarter worth about $29,000. Finally, Costello Asset Management INC purchased a new position in shares of Edwards Lifesciences during the first quarter valued at approximately $29,000. 79.46% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

EW has been the subject of a number of recent analyst reports. Canaccord Genuity Group boosted their price objective on Edwards Lifesciences from $75.00 to $81.00 and gave the company a "hold" rating in a report on Friday, July 25th. Piper Sandler upped their price target on shares of Edwards Lifesciences from $83.00 to $90.00 and gave the stock an "overweight" rating in a report on Friday, July 25th. The Goldman Sachs Group reaffirmed a "buy" rating on shares of Edwards Lifesciences in a research note on Friday, July 25th. Morgan Stanley boosted their target price on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the stock an "equal weight" rating in a research report on Tuesday, July 15th. Finally, Citigroup reissued a "buy" rating and set a $95.00 price target (up from $84.00) on shares of Edwards Lifesciences in a research report on Thursday, May 22nd. Three analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $85.90.

Edwards Lifesciences Price Performance

EW stock traded down $0.39 during midday trading on Tuesday, reaching $79.82. The stock had a trading volume of 1,146,197 shares, compared to its average volume of 4,431,117. Edwards Lifesciences Corporation has a 52-week low of $64.00 and a 52-week high of $83.00. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The company's fifty day simple moving average is $78.80 and its 200 day simple moving average is $75.26. The company has a market cap of $46.86 billion, a price-to-earnings ratio of 11.48, a price-to-earnings-growth ratio of 3.90 and a beta of 1.07.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating analysts' consensus estimates of $0.62 by $0.05. The business had revenue of $1.53 billion during the quarter, compared to analysts' expectations of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company's quarterly revenue was up 11.9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, sell-side analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other news, insider Larry L. Wood sold 8,950 shares of the company's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $75.23, for a total value of $673,308.50. Following the completion of the sale, the insider directly owned 206,900 shares in the company, valued at $15,565,087. This represents a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Daniel J. Lippis sold 4,114 shares of the business's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the transaction, the vice president directly owned 22,002 shares in the company, valued at $1,748,278.92. This trade represents a 15.75% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 22,014 shares of company stock worth $1,698,844. Insiders own 0.34% of the company's stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.